Equities analysts expect that Johnson & Johnson (NYSE:JNJ) will report $20.40 billion in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Johnson & Johnson’s earnings, with estimates ranging from $20.28 billion to $20.53 billion. Johnson & Johnson reported sales of $20.73 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.6%. The firm is expected to report its next quarterly earnings results before the market opens on Tuesday, October 13th.
On average, analysts expect that Johnson & Johnson will report full year sales of $80.86 billion for the current year, with estimates ranging from $80.43 billion to $81.26 billion. For the next fiscal year, analysts expect that the company will post sales of $87.73 billion, with estimates ranging from $86.42 billion to $88.93 billion. Zacks’ sales averages are a mean average based on a survey of research firms that cover Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. During the same period in the previous year, the company posted $2.58 earnings per share. Johnson & Johnson’s revenue for the quarter was down 10.8% on a year-over-year basis.
A number of research analysts have issued reports on JNJ shares. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $161.00 to $164.00 in a report on Monday, July 20th. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday, September 4th. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Citigroup upped their target price on Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $163.00.
NYSE:JNJ traded down $1.08 during trading hours on Wednesday, reaching $146.24. The company had a trading volume of 5,485,602 shares, compared to its average volume of 8,360,347. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The firm has a market cap of $385.02 billion, a PE ratio of 21.38, a price-to-earnings-growth ratio of 3.29 and a beta of 0.68. The business’s 50 day moving average price is $149.19 and its 200-day moving average price is $144.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date was Monday, August 24th. Johnson & Johnson’s payout ratio is currently 46.54%.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of JNJ. Victory Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 5.9% during the 1st quarter. Victory Capital Management Inc. now owns 2,757,100 shares of the company’s stock worth $361,539,000 after purchasing an additional 152,727 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $1,097,000. DC Investments Management LLC grew its holdings in shares of Johnson & Johnson by 11.8% during the 1st quarter. DC Investments Management LLC now owns 4,461 shares of the company’s stock worth $585,000 after purchasing an additional 470 shares during the period. Tradewinds Capital Management LLC grew its holdings in shares of Johnson & Johnson by 1.3% during the 1st quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock worth $997,000 after purchasing an additional 101 shares during the period. Finally, Hunter Associates Investment Management LLC grew its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Hunter Associates Investment Management LLC now owns 61,986 shares of the company’s stock worth $8,128,000 after purchasing an additional 334 shares during the period. Institutional investors own 67.44% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.